7Langholz E,Munkholm P,Davidsen M,et al.Course of ulcerative colitis:analysis of changes in disease activity over years.Gastroen- terology. 1994.107:3-11.
8Sandborn WJ.Current directions in IBD therapy:what goals are feasible with biological modifiers?Gastroenterology,2008,135: 1442-1447.
2Langholz E,Munkholm P,Davidsen M,et al.Course of ulcerative colitis:analysis of changes in disease activity over years.Gastroenterology,1994,107:3-11.
3Sandborn WJ.Current directions in IBD therapy:what goals are feasible with biological modifiers? Gastroenterology,2008,135:1442-1447.
4Faubion WA,Loftus EV,Harmsen WS,et al.The natural history of corticosteroid therapy for inflammatory bowel disease:a population-based study.Gastroenterology,2001,121:255-260.
5Ardizzone S,Maconi G,Russo A,et al.Randomized controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis.Gut,2006,55:47-53.
6Froslie KF,Jahnsen J,Moum BA,et al.Mucosal healing in inflammatory bowel disease:results from a Norwegian population-based cohort.Gastroenterology,2007,133:412-422.
7Sandborn W,Rutgeerts P,Feagan BG,et al.Infliximab reduces colectomy in patients with moderate to severe ulcerative colitis:colectomy analysis ACT1 and ACT2.Gut,2007,56(suppl Ⅲ):A26.
8Rutgeerts P,Vermeire S,Van Assche G,et al.Mucosal healing in inflammatory bowel disease:impossible ideal or therapeutic target.Gut,2007,56:453-455.
9Hommes D,Baert F,Van Assche G,et al.A Randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD):top-down versus step-up strategies.Gastroenterology,2005,128(suppl 2):A557.
10Panaccione R,Rutgeets P,Sandborn WJ,et al.Review article:treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.Aliment Pharmacol Ther,2008,28:674-688.
